Literature DB >> 22180477

NRP-1/CD304 expression in acute leukemia: a potential marker for minimal residual disease detection in precursor B-cell acute lymphoblastic leukemia.

Howard J Meyerson1, Georgetta Blidaru, Alison Edinger, Ebenezer Osei, Karen Schweitzer, Pingfu Fu, Linda Ho.   

Abstract

Neuropilin-1 (NRP-1)/CD304 is a marker for plasmacytoid dendritic cells. We determined the distribution of NRP-1/CD304 expression on normal hematopoietic cells and in 167 acute leukemias by flow cytometry. NRP-1/CD304 surface expression was frequent in precursor B-cell acute lymphoblastic leukemia (36/51 [71%]) and uncommon in acute myeloid leukemia (22.9%). In acute myeloid leukemia, expression was noted in all (4/4) acute myeloid leukemias with the M4eo subtype and in 50% of specimens (6/12) with complex cytogenetics. On hematopoietic cells, NRP-1/CD304 was expressed on normal erythroid progenitors, plasma cells, and B-cell progenitors, as well as plasmacytoid dendritic cells. Expression was not consistently detected on other hematopoietic cell types. Owing to this distribution of expression, the detection of NRP-1/CD304 alone on a hematopoietic cell cannot be used to determine plasmacytoid dendritic cell differentiation. Finally, we show that NRP-1/CD304 is overexpressed in 30% of precursor B-cell acute lymphoblastic leukemia samples compared with normal B-cell progenitors, allowing for its potential use as a marker for the detection of minimal residual disease.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22180477     DOI: 10.1309/AJCP6VDBL4BRXRQA

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  5 in total

1.  Expression of CD73 on leukemic blasts increases during follow-up - a promising candidate marker for minimal residual disease detection in pediatric B-cell precursor acute lymphoblastic leukemia.

Authors:  Łukasz Słota; Łukasz Sędek; Jan Kulis; Bartosz Perkowski; Iwona Malinowska; Joanna Zawitkowska; Bernarda Kazanowska; Katarzyna Derwich; Maciej Niedźwiecki; Agnieszka Mizia-Malarz; Katarzyna Muszyńska-Rosłan; Andrzej Kołtan; Grażyna Karolczyk; Katarzyna Machnik; Tomasz Urasiński; Monika Lejman; Wanda Badowska; Wojciech Młynarski; Jerzy Kowalczyk; Tomasz Szczepański
Journal:  Cent Eur J Immunol       Date:  2022-03-17       Impact factor: 1.634

2.  Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: A pitfall for minimal residual disease detection.

Authors:  Wenbin Xiao; Dalia Salem; Catharine S McCoy; Daniel Lee; Nirali N Shah; Maryalice Stetler-Stevenson; Constance M Yuan
Journal:  Cytometry B Clin Cytom       Date:  2017-10-31       Impact factor: 3.058

3.  Prognostic implication of neuropilin-1 upregulation in human nasopharyngeal carcinoma.

Authors:  Yu Xu; Peizhong Li; Xin Zhang; Junying Wang; Dongsheng Gu; Yao Wang
Journal:  Diagn Pathol       Date:  2013-09-20       Impact factor: 2.644

4.  Prognostic Impact of Neuropilin-1 Expression in Egyptian Children with B-lineage Acute Lymphoblastic Leukemia.

Authors:  Adel A Hagag; Nahla A Nosair
Journal:  Mediterr J Hematol Infect Dis       Date:  2015-01-01       Impact factor: 2.576

5.  Genetic status of KRAS modulates the role of Neuropilin-1 in tumorigenesis.

Authors:  Sneha Vivekanandhan; Lijuan Yang; Ying Cao; Engfeng Wang; Shamit K Dutta; Anil K Sharma; Debabrata Mukhopadhyay
Journal:  Sci Rep       Date:  2017-10-10       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.